NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
15 Mayo 2024 - 3:30PM
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:
NRXS), a medical technology company commercializing neuromodulation
therapies addressing chronic and debilitating conditions in
children and adults, will report summarized financial results for
its first quarter 2024, for the period ended March 31, 2024, on
Wednesday, May 22, 2024, before market open. The Company has
scheduled a conference call for the same day, Wednesday, May 22,
2024, at 9:00 am ET to review the results.
Filing of 10-QFollowing today’s
filing of a Form 12b-25 with the SEC, the Company expects to file
its Form 10-Q on Monday, May 20, 2024.
Conference Call Details
Date and Time: Wednesday, May
22, 2024, at 9:00am ET
Live Webcast Information:
Interested parties can access the conference call via a live
webcast, which is available in the Investor Relations section of
the Company’s website at
https://edge.media-server.com/mmc/p/jbecdhzi or
https://ir.neuraxis.com/. For participants listening through the
webcast, questions can be sent in through the portal using the “Ask
a Question” link or by emailing questions to
NRXS@lythampartners.com.
Call-in Information: Interested
parties can also access the live conference call by initially
registering at the following link. Upon completion of the
registration link, call-in participants will receive the dial-in
info and a unique PIN to join the call as well as an email
confirmation with the details.
Replay: A webcast replay will
be available in the Investor Relations section of the Company’s
website at https://edge.media-server.com/mmc/p/jbecdhzi or
https://ir.neuraxis.com/.
About NeurAxis, Inc.NeurAxis,
Inc., is a medical technology company focused on neuromodulation
therapies to address chronic and debilitating conditions in
children and adults. NeurAxis is dedicated to advancing science and
leveraging evidence-based medicine to drive adoption of its
IB-Stim™ therapy, which is its proprietary Percutaneous Electrical
Nerve Field Stimulation (PENFS) technology, by the medical,
scientific, and patient communities. IB-Stim™ is FDA cleared for
functional abdominal pain associated with irritable bowel syndrome
(IBS) in adolescents 11-18 years old. Additional clinical trials of
PENFS in multiple pediatric and adult conditions with large unmet
healthcare needs are underway. For more information, please
visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements other than statements of
historical fact are forward-looking statements. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results and other events may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. There are a number of important factors
that could cause actual results, developments, business decisions
or other events to differ materially from those contemplated by the
forward-looking statements in this press release. These factors
include, among other things, the conditions in the U.S. and global
economy, the trading price and volatility of the Company’s stock,
public health issues or other events, the Company’s compliance with
applicable laws, the results of the Company’s clinical trials and
perceptions thereof, the results of submissions to the FDA, the
results of the shareholder vote to enable the issuance of the
Preferred Stock, and factors described in the Risk Factors section
of NeurAxis’s public filings with the Securities and Exchange
Commission (SEC). Because forward-looking statements are inherently
subject to risks and uncertainties, you should not rely on these
forward-looking statements as predictions of future events. These
forward-looking statements speak only as of the date of this press
release and, except to the extent required by applicable law, the
Company undertakes no obligation to update or revise these
statements, whether as a result of any new information, future
events and developments or otherwise.
Contacts:
CompanyNeurAxis,
Inc.info@neuraxis.com
Investor RelationsBen
ShamsianLytham Partners646-829-9701shamsian@lythampartners.com
Neuraxis (AMEX:NRXS)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Neuraxis (AMEX:NRXS)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025